Phospho-p38 MAPK Expression in COPD Patients and Asthmatics and in Challenged Bronchial Epithelium

Davide Vallese\textsuperscript{a}  Fabio L.M. Ricciardolo\textsuperscript{b}  Isabella Gnemmi\textsuperscript{a}  Paolo Casolari\textsuperscript{c}  Paola Brun\textsuperscript{d}  Valentina Sorbelo\textsuperscript{b}  Armando Capelli\textsuperscript{a}  Francesco Cappello\textsuperscript{e,f}  Giorgio Narciso Cavallesco\textsuperscript{g}  Alberto Papi\textsuperscript{c}  Kian Fan Chung\textsuperscript{h}  Bruno Balbi\textsuperscript{a}  Ian M. Adcock\textsuperscript{h}  Gaetano Caramori\textsuperscript{c}  Antonino Di Stefano\textsuperscript{a}

\textsuperscript{a}Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell’Apparato Cardiorespiratorio, Fondazione Salvatore Maugeri, IRCCS, Veruno, \textsuperscript{b}Divisione di Pneumologia, Ospedale San Luigi, Università di Torino, Orbassano, \textsuperscript{c}Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-Correlate, Sezione di Medicina Interna e Cardiorespiratoria, Dipartimento di Scienze Mediche, and \textsuperscript{d}Dipartimento di Medicina Molare, Università di Padova, Padova, and \textsuperscript{e}Sezione di Anatomia Umana, Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Università di Palermo, and \textsuperscript{f}Euro-Mediterranean Institute of Science and Technology, Palermo, \textsuperscript{g}Section of General and Thoracic Surgery, Department of Morphology, Experimental Medicine and Surgery, Sant’Anna Hospital, University of Ferrara, Ferrara, Italy; \textsuperscript{h}National Heart and Lung Institute, Imperial College London, London, UK

Key Words
Mitogen-activated protein kinases · p65 · Pathology of chronic obstructive pulmonary disease · Chronic obstructive pulmonary disease phenotypes · Asthma phenotypes

Abstract
Background: The role of mitogen-activated protein kinases (MAPK) in regulating the inflammatory response in the airways of patients with chronic obstructive pulmonary disease (COPD) and asthmatic patients is unclear. Objectives: To investigate the expression of activated MAPK in lungs of COPD patients and in bronchial biopsies of asthmatic patients and to study MAPK expression in bronchial epithelial cells in response to oxidative and inflammatory stimuli. Methods: Immunohistochemical expression of phospho (p)-p38 MAPK, p-JNK1 and p-ERK1/2 was measured in bronchial mucosa in patients with mild/moderate (n = 17), severe/very severe (n = 16) stable COPD, control smokers (n = 16), control non-smokers (n = 9), in mild asthma (n = 9) and in peripheral airways from COPD patients (n = 15) and control smokers (n = 15). Interleukin (IL)-8 and MAPK mRNA was measured in stimulated 16HBE cells. Results: No significant differences in p-p38 MAPK, p-JNK or p-ERK1/2 expression were seen in bronchial biopsies and peripheral airways between COPD and control subjects. Asthmatics showed increased submucosal p-p38 MAPK expression compared to COPD patients (p < 0.003) and control non-smokers (p < 0.05). Hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}), cytomix (tumour necrosis factor-\alpha + IL-1\beta + interferon-\gamma) and lipopolysaccharide (LPS) upregulated IL-8 mRNA at 1 or 2 h. p38 MAPK\textalpha mRNA was significantly increased after H\textsubscript{2}O\textsubscript{2} and LPS treatment. JNK1 and ERK1 mRNA were unchanged after H\textsubscript{2}O\textsubscript{2}, cytomix or LPS treatments. Conclusion: p-p38 MAPK expression is similar in stable COPD and control subjects but increased in the bronchi of mild...


Introduction

The mitogen-activated protein kinase (MAPK) family includes 3 distinct stress-activated protein kinase pathways: p38, c-Jun N-terminal kinase (JNK) and extracellular regulating kinase (ERK) [1]. The ERK pathway is predominantly activated by mitogenic and proliferative stimuli, whereas the JNK and p38 MAPK respond to environmental stresses [1]. A potential role of activated p38 MAPK has been reported for neutrophil and eosinophil lung cell migration, cytokine release from inflammatory cells and airway smooth muscle, release of matrix metalloproteinases, Th1 cell differentiation and interferon-gamma production and induction of corticosteroid insensitivity [2]. MAPK and the pro-inflammatory transcription factor nuclear factor-kB (NF-kB) are activated in airway epithelial cells and macrophages exposed to different stimuli such as lipopolysaccharide (LPS), cigarette smoke extracts and oxidants [3–8]. The production of mucin by airway epithelial cells is induced by oxidants and is accompanied by p38 MAPK phosphorylation and activation [6]. Cigarette smoke exposure of airway epithelial cells resulted in upregulation of interleukin (IL)-6 and IL-8 mediated by p38 MAPK and NF-kB [9]. Rhinovirus exposure of human macrophages induces p38 MAPK activation and release of CCL1 (monocyte chemoattractant protein-1) [10]. Increased phospho (p)-p38 MAPK immunopositivity was reported in lung alveolar septa of chronic obstructive pulmonary disease (COPD) patients when compared to control smokers and non-smokers [11], whilst p-p38 MAPK expression in lymphocytes within the submucosa of peripheral airways was similar in COPD patients, control smokers and non-smokers [12]. In bronchial biopsies of asthmatics, epithelial staining for p-p38 MAPK and p-ERK1/2 was increased compared to healthy controls, while healthy subjects showed the highest p-JNK intensity [13]. MAPK expression and activation have not been studied to date in bronchial biopsies of COPD patients. Due to the role of p38 MAPK in inducing inflammation, p38 MAPK inhibitors have recently been studied, particularly in severe asthmatics and COPD patients [2]. The results obtained in these clinical trials are not particularly encouraging [14–16].

In COPD, the airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases [17, 18]. Previous studies have emphasized the potential role of p38 MAPK in the pathogenesis of COPD and asthma [2]. However, the mechanisms of inducing p38 MAPK up-regulation and its participation in the inflammatory state in the bronchi of COPD patients are not yet fully clarified.

The present study aimed: (1) to investigate MAPK expression in the bronchial biopsies and peripheral Airways of patients with COPD and to compare these findings with control smokers, non-smoking subjects and a group of asthmatics, and (2) to investigate MAPK mRNA expression in vitro in bronchial epithelial cells in response to oxidative (H2O2) and inflammatory (LPS, cytomix) stimuli which are implicated in COPD and asthma.

Methods

Subjects

All COPD and healthy control subjects who underwent bronchoscopy and bronchial biopsy collection were recruited from the Respiratory Medicine Unit of the Fondazione Salvatore Maugeri (Veruno, Italy). Asthmatics were recruited from the Division of Pneumology, Ospedale San Luigi, Orbassano, University of Torino, and the severity of asthma was classified according to the GINA and ATS criteria [19, 20]. In COPD patients, the severity of the airflow obstruction was staged using current GOLD criteria (www.goldcopd.com). All former smokers had stopped smoking for at least 1 year. COPD and chronic bronchitis were defined, according to international guidelines, as follows: COPD, presence of a post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <70%; levels of shortness of breath, chronic cough, sputum and numbers of exacerbations per year were also taken into account as suggested by new GOLD criteria; chronic bronchitis, presence of cough and sputum production for at least 3 months in each of 2 consecutive years [18]. All COPD patients were stable with no previous exacerbation in the 6 months before bronchoscopy. None of the COPD patients was treated with theophylline, antibiotics, antioxidants, mucolytics and/or glucocorticoids in the month prior to the bronchial biopsy. The peripheral lung tissues were collected at the University Hospital of Ferrara, during lung resection for a solitary peripheral neoplasm, and all subjects were not under regular treatment with glucocorticoids and/or bronchodilators. Asthmatics were under therapy following GINA criteria [19]. The study conformed to the Declaration of Helsinki and was approved by the ethics committees of the Fondazione Salvatore Maugeri, Veruno (Novara), San Luigi Hospital, Orbassano (Torino), and the University Hospital of Ferrara, Italy; written informed consent was obtained from each participant, and bronchial biopsies were performed according to the guidelines of the local ethics committee.

Vallese et al.

DOI: 10.1159/000375168

Respiration

© 2015 S. Karger AG, Basel
Lung Function Tests and Volumes
Pulmonary function tests were performed as previously described [21] according to guideline recommendations [22]. Pulmonary function tests included measurements of FEV1 and FEV1/FVC under baseline conditions in all the subjects examined (6200 Autobox Pulmonary Function Laboratory, Sensormedics Corp., Torba Linda, Calif., USA). In order to assess the reversibility of airflow obstruction and postbronchodilator functional values, the FEV1 and FEV1/FVC percent measurements in the groups of subjects with FEV1/FVC ≤ 70% before bronchodilator use was repeated 20 min after the inhalation of 0.4 mg of salbutamol.

Immunohistochemistry on OCT-Embedded Bronchial Biopsies
One cryostat section from each biopsy was stained applying immunohistochemical methods with a panel of antibodies specific for inflammatory cells (CD4+, CD8+, CD68+, neutrophil elastase+) or p-MAPK (Table 1). Briefly, after blocking non-specific binding sites with serum derived from the same animal species as the secondary antibody, primary antibody was applied at optimal dilutions in Tris-buffered saline (0.15 M saline containing 0.05 M Tris-hydrochloric acid at pH 7.6) and incubated for 1 h at room temperature in a humid chamber. Antibody binding was demonstrated with secondary anti-mouse (Vector, BA 2000) or anti-rabbit (Vector, BA 1000) antibodies followed by ABC kit ((Vector, BA 1000) antibodies followed by ABC kit AP AK5000 Vectastain and fast red substrate (red colour) or ABC kit HR Elite, PK6100, Vectastain and diaminobenzidine substrate (brown colour). Human tonsils or nasal polyps were used as positive controls. For the negative control, normal mouse or rabbit non-specific immunoglobulins (Santa Cruz Biotechnology, Santa Cruz, Calif., USA) were used at the same protein concentration as the primary antibody.

Immunohistochemistry in Human Peripheral Lung Tissue
Immunostaining of paraffin-embedded peripheral lung tissue was performed as previously described [23]. After deparaffinization and rehydration to expose the immunoreactive epitopes, the sections were to be stained, immersed in retrieval solution citrate, pH 6.0, or EDTA, pH 8.0, were incubated in a microwave oven (model NN S200W; Panasonic, Milano, Italy) on high power for 40 min. Endogenous peroxidase activity was blocked by incubating slides in 3% H2O2 in PBS followed by washing in PBS. Cell membranes were permeabilized adding 0.1% saponin to the PBS. Non-specific labelings were blocked by coating with blocking serum (5% normal goat serum) for 20 min at room temperature. After washing in PBS the sections were treated with the following primary antibodies: rabbit monoclonal p-p38 MAPK (p-Thr180/p-Tyr182; code 1229-1) and rabbit p-ERK1/p-ERK2 (p-Thr202/p-Tyr204; code 1229-1), both

<table>
<thead>
<tr>
<th>Primary antibody</th>
<th>Origin</th>
<th>ID</th>
<th>Secondary antibody</th>
<th>Dilution</th>
<th>Positive control</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-p38</td>
<td>Santa Cruz</td>
<td>SC-17852-R</td>
<td>Rabbit</td>
<td>1:150</td>
<td>Nasal polyp, human tonsil</td>
</tr>
<tr>
<td>p-JNK1</td>
<td>Abcam</td>
<td>Ab-18680</td>
<td>Rabbit</td>
<td>1:150</td>
<td>Nasal polyp, human tonsil</td>
</tr>
<tr>
<td>p-ERK1/2</td>
<td>Epitomics</td>
<td>1481-1</td>
<td>Rabbit</td>
<td>1:100</td>
<td>Nasal polyp, human tonsil</td>
</tr>
<tr>
<td>CD4</td>
<td>Dako</td>
<td>M716</td>
<td>Mouse</td>
<td>1:100</td>
<td>Nasal polyp, human tonsil</td>
</tr>
<tr>
<td>CD8</td>
<td>Dako</td>
<td>M7103</td>
<td>Mouse</td>
<td>1:200</td>
<td>Nasal polyp, human tonsil</td>
</tr>
<tr>
<td>CD68</td>
<td>Dako</td>
<td>M814</td>
<td>Mouse</td>
<td>1:200</td>
<td>Nasal polyp, human tonsil</td>
</tr>
<tr>
<td>Neutrophil elastase</td>
<td>Dako</td>
<td>M752</td>
<td>Mouse</td>
<td>1:100</td>
<td>Nasal polyp, human tonsil</td>
</tr>
</tbody>
</table>

Table 1. Primary antibodies and immunohistochemical conditions used for identification of MAPK and inflammatory cells

MAPK Expression Related to Different Challenges in COPD and Asthma

DOI: 10.1159/000375168

Respiration
obtained from Epitomics, and mouse monoclonal anti-p-SAPK/JNK (Thr183/Tyr185; www.scbt.com; code sc6254) at the dilution of 1:25, 1:50 and 1:300, respectively. Sometimes we have used different primary antibodies for the immunohistochemical and the Western blotting (see below) studies because the cell signalling technology does not provide the concentration of their primary antibody, and this does not allow the use of appropriate negative controls (non-specific IgG at the same concentration of the primary antibody) for immunohistochemical studies. For the negative control slides normal rabbit or mouse non-specific immunoglobulins (Santa Cruz Biotechnology) were used at the same protein concentration as the primary antibody. Control slides were included in each staining run using human normal tonsils (kindly provided by Prof. Stefano Pelucchi, ENT Section at the University of Ferrara, Italy) as a positive control for all the immunostaining performed. After repeated washing steps with PBS, the sections were subsequently incubated with goat anti-rabbit or horse anti-mouse biotinylated antibody (Vector ABC Kit, Vector Laboratories; www.vectorlabs.com) for 30 min at room temperature. After further washing, the sections were subsequently incubated with ABC reagent (Vector ABC kit, Vector Laboratories) for 30 min at room temperature. Slides were then incubated with chromogen-fast diaminobenzidine as chromogenic substrate, after which they were counterstained in haematoxylin and mounted on permanent mounting medium.

**Scoring System for Immunohistochemistry in the Bronchial Biopsies**

Morphometric measurements were performed with a light microscope (Leitz Biomed, Leica, Cambridge, UK) connected to a videocamera (Leitz Wetzlar) and stored on a computerized image system (Quantimet 500 Image Processing and Analysis System, Software Qwin V0200B, Leica). Light-microscopic analysis was performed at a magnification of ×630.

The immunostaining for all antigens studied was scored (range: 0 = absence of immunostaining to 3 = extensive intense immunostaining) in the intact (columnar and basal epithelial cells) bronchial epithelium, as previously described [21]. The final result was expressed as the average of all scored fields performed in each biopsy. A mean ± SD of 0.700 ± 0.260 mm of epithelium was analysed in COPD patients and control subjects. Immunostained cells in bronchial biopsy lamina propria were quantified 100 μm beneath the epithelial basement membrane in several non-overlapping high-power fields until the whole specimen was examined. The final result, expressed as the number of positive cells per square millimetre, was calculated as the average of all the cellular counts performed in each biopsy.

**Scoring System for Immunohistochemistry in the Peripheral Lung Tissue**

Staining analysis was performed as previously described [24]. Staining data were interpreted blinded with no prior knowledge of the clinicopathological parameters. A bronchiole was taken to be an airway with no cartilage and glands in its wall. To count the number of positive cells on the sections stained for p-p38 MAPK, p-JNK and p-ERK, the area of bronchiolar epithelium to be studied was selected randomly. Cells with nuclear immunostaining were counted on each of 10 consecutive, non-overlapping, high-power fields (about 300 cells) with 1 count on each of 3, when available, bronchioles for each section stained. Results were expressed as percentages of total bronchiolar epithelial cells counted.

To quantify kinase expression in alveolar macrophages, at least 20 high-power fields of lung parenchyma were randomly selected for each section, and at least 100 macrophages inside alveoli were evaluated. Alveolar macrophages were defined as mononuclear cells with well-represented cytoplasm present in the alveolar spaces and not attached to the alveolar walls using a previously validated method [25]. Results were expressed as percentages of total alveolar macrophages counted.

**Western Blot Analysis for p-p38 MAPK, p-JNK and p-ERK in the Peripheral Lung**

Whole cell protein extraction from peripheral lung parenchyma, gel electrophoresis and nitrocellulose filter transfer were performed as previously described [21]. After blocking for 45 min at room temperature in Tris-buffered saline, 0.05% Tween-20 and 5% non-fat dry milk, filters were incubated with rabbit anti-p-p38 MAPK (Cell Signalling, monoclonal antibody No. 9215) or rabbit anti-p-JNK (Abcam, Ab-18680) or rabbit anti-p-ERK1/2 (Epitomics, 1481-1) for 1 h at room temperature in Tris-buffered saline, 0.05% Tween-20 and 5% non-fat dry milk at a dilution of 1:500 to 1:1,000 (0.1–0.2 μg/ml). HeLa cells were used as positive controls. After washing, filters were incubated with goat anti-rabbit (Dako, UK) antibody conjugated to horseradish peroxidase at a dilution of 1:4,000. Visualization was performed using enhanced chemiluminescence as recommended by the manufacturer (Amersham Pharmacia Biotech). Anti-human actin antibody (Santa Cruz Biotechnology) was used as an internal control. Bands were quantified using densitometry with Grab-It and VisionWorks LS software (UVP, Cambridge, UK) and expressed as a ratio with the corresponding actin optical density value of the same line.

**Cell Culture and Treatments**

We used the SV40 large T antigen-transformed 16HBE cell line that retains the differentiated morphology and function of normal human bronchial epithelial cells [26]. For experiments 16HBE cells were passaged using Dulbecco’s modified minimum essential medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 50 IU/ml penicillin, 50 μg/ml streptomycin, 1× non-essential amino acids, 1 mM sodium pyruvate and 2 mM glutamine (37°C, 5% CO2). When cells were at 60–70% confluence, the complete medium was replaced with DMEM without FBS for starvation time (24 h), followed by DMEM plus 1% FBS in the absence or presence of H2O2 (100 μM), cytokim (TNF-α 10 ng/ml + IL-1β 1 ng/ml + IFN-γ 10 ng/ml; R&D System), LPS from *Pseudomonas aeruginosa* (Sigma, L9143; 10 μg/ml), at 1, 2 and 4 h. Passage numbers of cells used in this study ranged from 22 to 24. All experiments were performed at least in quadruplicate for 4 independent experiments for each type of treatment (H2O2, cytokim, LPS) and each time of exposure (1, 2, 4 h).

**Extraction and Quantification of RNA and qRT-PCR from 16HBE**

Total cellular RNA from exposed and non-exposed cultures was purified and isolated using an RNAspin Mini RNA Isolation kit (GE Healthcare) following the manufacturer’s instructions. Total RNA was resuspended in 100 μl nuclelease-free water. RNA concentration was determined using a UV/visible spectrophotometer (λ 260/280 nm, Eppendorf BioPhotometer plus) and stored at −80°C.

Vallese et al.
The expression of genes of interest was measured using Syber green (Qiagen, UK) for qPCR in a Corbett Rotor Gene 6 (Corbett, Cambridge, UK) system. One-step real-time PCR was carried out by amplifying mRNA using the QuantiFast™ Syber green RT-PCR kit (Qiagen, Italy) according to the manufacturer’s instructions and the respective primers (Qiagen, Italy). We detected the expression of CXCL8 (IL-8; cat. QT00000322, Qiagen), p38α (cat. QT00079345), JNK1 (cat. QT00091056), ERK1 (cat. QT00065933) and NF-κB p65 (cat. QT01007370) mRNA after reverse transcription using the Stat View SE Graphics program (Abacus Concepts Inc., Berkeley, Calif., USA).

Patients were classified according to GOLD (http://www-goldcopd.com) levels of severity for COPD into mild (stage I), moderate (stage II), severe (stage III) and very severe (stage IV). Mild asthmatics were classified according to the GINA and ATS criteria. Data are means ± SD. For COPD and asthmatic patients FEV$_1$/FVC (%) are postbronchodilator values. M = Male; F = female; BD = bronchodilator; n.d. = not determined. Statistics (ANOVA): a $p < 0.0001$, significantly different from control smokers with normal lung function and control never-smokers; b $p < 0.0001$, significantly different from mild/moderate COPD; c $p < 0.05$, significantly different from control smokers with normal lung function.

### Table 2. Clinical characteristics of COPD, asthmatics and control subjects studied by bronchial biopsy analysis

<table>
<thead>
<tr>
<th>Groups</th>
<th>n</th>
<th>Age, years</th>
<th>M/F</th>
<th>Pack-years</th>
<th>Ex/current smokers</th>
<th>FEV$_1$ before BD, % pred.</th>
<th>FEV$_1$ after BD, % pred.</th>
<th>FEV$_1$/FVC, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control non-smokers</td>
<td>9</td>
<td>64±10</td>
<td>8/1</td>
<td>0</td>
<td>0</td>
<td>112±15</td>
<td>n.d.</td>
<td>89±12</td>
</tr>
<tr>
<td>Control smokers with normal lung function</td>
<td>16</td>
<td>60±9</td>
<td>11/5</td>
<td>43±29</td>
<td>4/12</td>
<td>100±13</td>
<td>n.d.</td>
<td>81±6</td>
</tr>
<tr>
<td>COPD stages I and II (mild/moderate)</td>
<td>17</td>
<td>71±8</td>
<td>14/3</td>
<td>50±28</td>
<td>6/11</td>
<td>63±11$^a$</td>
<td>67±13</td>
<td>57±4$^a$</td>
</tr>
<tr>
<td>COPD stages III and IV (severe/very severe)</td>
<td>16</td>
<td>70±16</td>
<td>10/6</td>
<td>59±39</td>
<td>12/4</td>
<td>36±8$^a,b$</td>
<td>43±9</td>
<td>43±11$^a,b$</td>
</tr>
<tr>
<td>Asthmatics</td>
<td>9</td>
<td>66±8</td>
<td>5/4</td>
<td>0</td>
<td>–</td>
<td>85±17</td>
<td>97±17</td>
<td>81±10</td>
</tr>
</tbody>
</table>

Groups were age-matched. The smoking history was similar in the 3 smoking groups. Values of FEV$_1$ (% predicted) and FEV$_1$/FVC (%) were significantly different in the groups with mild/moderate and severe/very severe COPD compared to both control groups (healthy smokers and healthy non-smokers). Severe/very severe COPD patients also differed significantly from mild/moderate COPD patients (for overall groups, ANOVA test: p < 0.0001 for FEV$_1$ % predicted and FEV$_1$/FVC % values). Thirty-six percent (n = 12) of the total COPD patients and 25% (n = 4) of healthy smokers with normal lung function also had symptoms of chronic bronchitis. There was no significant difference when COPD patients and healthy smokers were compared for the presence of chronic bronchitis. For comparative purposes related to the expression of p-

**Results**

**Clinical Characteristics of Subjects Studied by Immunohistochemistry**

We obtained and studied bronchial biopsies from 58 subjects: 33 with stable COPD, 16 were current or ex-smokers with normal lung function, and 9 were non-smokers with normal lung function (table 2). COPD patients were divided into 2 groups: mild/moderate (GOLD stage I–II, n = 17) and severe/very severe (GOLD stage III–IV, n = 16; www.goldcopd.com). Subjects in all 4 groups were age-matched. The smoking history was similar in the 3 smoking groups. Values of FEV$_1$ (% predicted) and FEV$_1$/FVC (%) were significantly different in the groups with mild/moderate and severe/very severe COPD compared to both control groups (healthy smokers and healthy non-smokers). Severe/very severe COPD patients also differed significantly from mild/moderate COPD patients (for overall groups, ANOVA test: p < 0.0001 for FEV$_1$ % predicted and FEV$_1$/FVC % values). Thirty-six percent (n = 12) of the total COPD patients and 25% (n = 4) of healthy smokers with normal lung function also had symptoms of chronic bronchitis. There was no significant difference when COPD patients and healthy smokers were compared for the presence of chronic bronchitis. For comparative purposes related to the expression of p-
MAPK in the bronchi of COPD patients and asthmatics, we also studied bronchial biopsies from 9 stable age-matched mildly asthmatic patients. Clinical characteristics of asthmatics are included in table 2. Asthmatics were using short-acting bronchodilators on demand. Two out of 9 asthmatics were using inhaled corticosteroids at low doses.

We studied peripheral lung specimens from 15 stable COPD patients and 15 control smokers with normal lung function matched for their age and smoking history (table 3).

Measurement of Inflammatory Cells in the Bronchial Submucosal Biopsies of COPD Patients

These data, obtained from stable COPD patients by immunohistochemistry, confirm previously reported higher numbers of neutrophils and CD8+ cells in severe/very severe COPD (table 4) [28]. COPD patients with chronic bronchitis had a similar number of neutrophils when compared with COPD patients without chronic bronchitis [21, 28].

Table 3. Characteristics of subjects for the immunohistochemistry and Western blotting studies on the peripheral lung tissue

<table>
<thead>
<tr>
<th>Subjects</th>
<th>n</th>
<th>Age, years</th>
<th>M/F</th>
<th>Ex/current smokers</th>
<th>Pack-years</th>
<th>Chronic bronchitis (yes/no)</th>
<th>FEV1, % pred.</th>
<th>FEV1/FVC, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control smokers</td>
<td>15</td>
<td>66±7</td>
<td>12/3</td>
<td>8/7</td>
<td>40±34</td>
<td>7/8</td>
<td>100.3±15.6</td>
<td>77±3.7</td>
</tr>
<tr>
<td>COPD patients</td>
<td>15</td>
<td>69±7</td>
<td>13/2</td>
<td>8/7</td>
<td>42±22</td>
<td>7/8</td>
<td>72.4±20*</td>
<td>58±9.7*</td>
</tr>
</tbody>
</table>

Data are expressed as means ± SD. M = Male; F = female. For COPD patients and smokers with normal lung function, FEV1 and FEV1/FVC are postbronchodilator values. Statistics (ANOVA): * p < 0.001, significantly different from control smokers with normal lung function.

Table 4. Immunohistochemical quantification of inflammatory cells and MAPK related to inflammatory response in bronchial mucosa

<table>
<thead>
<tr>
<th></th>
<th>Control non-smokers</th>
<th>Control smokers</th>
<th>Mild/moderate COPD</th>
<th>Severe/very severe COPD</th>
<th>Kruskal-Wallis p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epithelium (score 0–3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-p38</td>
<td>0.75 (0.25–1)</td>
<td>0.75 (0.25–1.25)</td>
<td>0.5 (0.25–1.25)</td>
<td>0.5 (0.25–1.5)</td>
<td>0.618</td>
</tr>
<tr>
<td>p-JNK1</td>
<td>0.12 (0–0.25)</td>
<td>0.1 (0–1)</td>
<td>0.12 (0–1)</td>
<td>0.25 (0–1)</td>
<td>0.521</td>
</tr>
<tr>
<td>p-ERK1/2</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>0 (0–0)</td>
<td>n.a.</td>
</tr>
<tr>
<td>Submucosa, cells/mm²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-p38</td>
<td>89 (27–118)</td>
<td>105 (32–155)</td>
<td>52 (20–106)</td>
<td>49 (27–161)</td>
<td>0.223</td>
</tr>
<tr>
<td>p-JNK1</td>
<td>5 (0–20)</td>
<td>7 (0–45)</td>
<td>17 (0–64)</td>
<td>11 (3–51)</td>
<td>0.262</td>
</tr>
<tr>
<td>p-ERK1/2</td>
<td>0 (0–6)</td>
<td>0 (0–21)</td>
<td>0 (0–13)</td>
<td>0 (0–2)</td>
<td>0.212</td>
</tr>
<tr>
<td>CD4</td>
<td>164 (101–212)</td>
<td>246 (37–500)</td>
<td>258 (107–731)</td>
<td>252 (66–470)</td>
<td>0.206</td>
</tr>
<tr>
<td>CD8</td>
<td>147 (76–301)</td>
<td>179 (86–657)</td>
<td>195 (86–523)</td>
<td>244 (111–355)</td>
<td>0.365</td>
</tr>
<tr>
<td>CD68</td>
<td>284 (128–516)</td>
<td>275 (97–904)</td>
<td>367 (158–759)</td>
<td>340 (204–1,054)</td>
<td>0.671</td>
</tr>
<tr>
<td>Neutrophil elastase</td>
<td>93 (58–166)</td>
<td>97 (45–308)</td>
<td>94 (28–512)</td>
<td>151 (47–470)</td>
<td>0.045</td>
</tr>
</tbody>
</table>

n.a. = Not applicable. Data expressed as medians (ranges). Statistics: the Kruskal-Wallis test was used for multiple comparisons followed by the Mann-Whitney U test for comparison between groups; a p < 0.05, significantly different from control non-smokers; b p < 0.05, significantly different from control smokers with normal lung function; the exact p values for comparison between groups are given in the Results section.
control non-smokers (p = 0.958), severe/very severe COPD (p = 0.385), mild/moderate COPD (p = 0.247) or all COPD patients (p = 0.249; fig. 1). Similarly, no significant differences were observed for p-JNK1 between asthmatics (median 0.125, range 0–0.25) and control non-smokers (p = 0.957), severe/very severe COPD (p = 0.270), mild/moderate COPD (p = 0.345) or all COPD patients (p = 0.256). No significant differences were observed for p-ERK1/2 between asthmatics (median 0, range 0–0) and control non-smokers (p > 0.999), severe/very severe COPD (p > 0.999), mild/moderate COPD (p > 0.999) or all COPD patients either (p > 0.999).

Immunohistochemistry in the Bronchial Submucosal Biopsies
In COPD and control subjects the most frequently expressed MAPK in bronchial submucosa was, as for epithelium, p-p38 MAPK. It was mainly expressed by mononuclear cells and occasionally by endothelial cells. p-JNK1 was poorly expressed in all groups studied, and p-ERK1/2 was only occasionally found. In COPD patients and control subjects no significant differences between groups were observed for all p-MAPK studied (table 4; fig. 2). Interestingly, asthmatics showed higher levels of p-p38 MAPK protein (median 125, range 54–387) when compared to control non-smokers (p = 0.040), severe/very severe COPD (p = 0.013), mild/moderate COPD (p = 0.0018) or all COPD patients (p = 0.0016; fig. 1). No significant differences were observed for p-JNK1/mm2 counted in asthmatics (median 13, range 5–161) when compared to control non-smokers (p = 0.112), severe/very severe COPD (p = 0.654), mild/moderate COPD (p = 0.571) or all COPD patients (p = 0.570). No significant differences were observed for p-ERK1/2/mm2

Fig. 1. Photomicrographs showing the bronchial mucosa from an asthmatic subject (a) and a patient with COPD (b) immunostained for identification of p-p38+ cells (arrows). Results are representative of those from 33 (mild/moderate and severe/very severe) COPD patients and 9 mild asthmatics. Column bar graphs indicate median (and interquartile range) values of p-p38 scored in the epithelium (c) and p-p38+ cells quantified in the submucosa (d) of all COPD patients (n = 33) and asthmatics (n = 9) studied. p values are based on the Mann-Whitney test for comparison between groups.
Fig. 2. Photomicrographs showing the bronchial mucosa from control non-smokers (a–c) and patients with mild/moderate COPD (d–f) immunostained (arrows) for identification of p-p38 (a, d), p-JNK1 (b, e) and p-ERK1/2 (c, f) in the bronchial epithelium and submucosa. Results are representative of those from 9 non-smokers and 33 COPD patients. g Negative control immunostaining, performed in a nasal polyp section, including an irrelevant rabbit primary antibody.
counted between asthmatics (median 5, range 0–17) and control non-smokers (p = 0.216), mild/moderate COPD (p = 0.608) or all COPD patients (p = 0.156). A slight but significant increase was observed in asthmatics in comparison with severe/very severe COPD (p = 0.034).

Immunohistochemistry in the Peripheral Lung Tissue

In the peripheral airways no significant differences were observed for percentages of p-p38 MAPK immunostained bronchiolar epithelial cells between COPD (median 68, range 10–100) and control smokers (70, range 40–100; p = 0.9181). Percentages of p-p38 MAPK+ alveolar macrophages in COPD (median 87, range 60–100) versus control smokers (94, range 82–100; p = 0.5265) were not significantly different either (fig. 3).

No significant differences were observed for percentages of p-JNK immunostained bronchiolar epithelial cells between COPD (median 38, range 2–64) and control smokers (36, range 5–58; p = 0.5439). Percentages of p-JNK+ alveolar macrophages in COPD (median 88, range 60–100) versus control smokers (90, range 40–100; p = 0.3216) were not significantly different (fig. 4).

No significant differences were observed for percentages of p-ERK1/2-immunostained bronchiolar epithelial cells between COPD (median 40, range 0–90) and control smokers (37, range 0–70; p = 0.5495). Percent-

Fig. 3. a Western blot analysis of activated p-p38 MAPK in snap-frozen peripheral lung lysates of stable COPD (n = 9) and age-matched control smokers with normal lung function (n = 7) with actin as the control for loading. b Graphical analysis of the densitometric ratio (arbitrary units, AU) of p-p38 MAPK/actin. c Immunohistochemical images of p-p38 MAPK immunostaining in bronchiolar epithelial cells and alveolar macrophages representative of 15 COPD and 15 control smokers. Magnification ×400. Bar = 50 μm. d, e Graphical presentation of the percentage of epithelial and macrophage staining.

MAPK Expression Related to Different Challenges in COPD and Asthma

Respiration

DOI 10.1159/000375168
ages of p-ERK1/2+ alveolar macrophages in COPD (median 75, range 25–100) versus control smokers (72, range 8–100; \( p = 0.8682 \)) were not significantly different either (fig. 4).

Western Blotting for p-p38 MAPK, p-JNK and p-ERK1/2 in Peripheral Lung Tissue

No significant differences were observed for the p-p38 MAPK/actin ratio between COPD (median 1.02, range 0.2–1.40) and control smokers (1.0, range 0.65–1.30; \( p = 1.0000 \); fig. 3), the p-JNK/actin ratio between COPD (median 0.10, range 0.05–0.13) and control smokers (0.10, range 0.06–0.12; \( p = 0.4079 \); fig. 4) and the p-ERK1/2/actin ratio between COPD (median 0.10, range 0.05–0.13) and control smokers (0.10, range 0.06–0.12; \( p = 0.4079 \); fig. 4).

Correlations between p-MAPK Cell Counts, Clinical Parameters and Inflammatory Cells in the Bronchial Biopsies

In all smokers and in patients with COPD alone we did not observe any significant correlation between numbers of p-p38+, p-JNK1+ and p-ERK1/2+ cells per square millimetre and numbers of cigarettes smoked (pack-years), functional (spirometry values and clinical parameters) data or structural (inflammatory cells) data.

MAPK, NF-κB p65 and IL-8 mRNA Expression in 16HBE Cells Induced by Oxidative and Inflammatory Stimuli in vitro

Human bronchial epithelial (16HBE) cells were stimulated with \( \text{H}_2\text{O}_2 \) (100 \( \mu \)M), cytomix (TNF-α, 10 ng/ml, IL-1β, 1 ng/ml, and IFN-γ, 10 ng/ml) and LPS (10 \( \mu \)g/ml), and the expression of IL-8 (fig. 5a), p38 MAPKα (fig. 5b), JNK1 (fig. 5c), ERK1 (fig. 5d) and NF-κB p65 subunit (fig. 5e) mRNA was quantified by qRT-PCR. IL-8 mRNA was significantly increased 2 h after \( \text{H}_2\text{O}_2 \) (\( p < 0.0001 \)), 1 and 2 h after cytomix (\( p = 0.001 \) and \( p = 0.017 \), respectively), and 2 h after LPS (\( p = 0.010 \)) but it did not change after cytomix treatment (fig. 5b). JNK1 mRNA was not significantly changed by any of the treatments used (fig. 5c). ERK1 mRNA was not significantly increased after \( \text{H}_2\text{O}_2 \), cytomix or LPS treatments (fig. 5d). NF-κB p65 subunit mRNA was significantly increased...
Fig. 5. In vitro expression of CXCL8 (IL-8; a), p38α (b), JNK1 (c), ERK1 (d) and NF-κB p65 subunit (e) mRNA in 16HBE cells treated with H$_2$O$_2$ (100 μM), cytomix (TNF-α, 10 ng/ml, IL-1β, 1 ng/ml, and IFN-γ, 10 ng/ml) and LPS from P. aeruginosa. All treatments upregulated IL-8 mRNA expression 1 or 2 h after treatment (a). H$_2$O$_2$ stimulation upregulated p38 (b) and p65 (e) mRNA 2 h after stimuli. LPS upregulated p-38 (b) mRNA 1 h after stimulus. All experiments were performed in quadruplicate. Data are expressed as means ± standard deviation. Statistical analysis: t test (* p < 0.05) for comparison between treated (TR) and non-treated (NT) cells. The exact p values for comparison between groups are given in the Results section.
Discussion

This study shows similar immune expression of p-p38 MAPK, p-JNK1 and p-ERK1/2 in the bronchial epithelium and submucosa of patients with mild/moderate and severe/very severe stable COPD when compared to control smokers and control non-smokers. Activated MAPK were also similarly expressed in the bronchiolar epithelium of stable COPD patients compared to control smokers with normal lung function. p-p38 MAPK immunopositivity in the bronchial submucosa of asthmatics was significantly increased when compared to stable COPD and control non-smokers. Interestingly, bronchiolar epithelial cells (16HBE) exposed in vitro to H2O2, cytomix and LPS showed increased levels of IL-8 mRNA production which were accompanied by a parallel increase in p38 MAPK mRNA after H2O2 and LPS stimulation but not by a parallel increase in JNK1 and ERK1 mRNA. In patients with COPD, p-p38 MAPK immunopositivity was increased in the small airway epithelium [12] when compared to control non-smokers [12] and in alveolar septa [11] when compared to control smokers and non-smokers [11]. p-p38 MAPK immunopositivity in lymphocytes populating the submucosa of peripheral airways of COPD patients was similar to that found in control smokers and non-smokers [12]. These last data are in part in agreement with our present observations of no changes of p-p38 MAPK immunopositivity in the bronchial biopsy submucosa of stable COPD patients compared to control smokers and non-smokers, peripheral airway bronchiolar epithelium of stable COPD patients compared to control smokers, and with our observation of the absence of significant changes in total p-p38 MAPK protein, measured by Western blot, using lung tissue, when comparing stable COPD patients and control smokers with normal lung function. In fact, p-p38 MAPK immunopositivity in our bronchial biopsy specimens was mainly observed in mononuclear cells and occasionally in endothelial cells, and in agreement with Gaffey et al. [12], the mononuclear cell component expressing p-p38 MAPK immunopositivity was similar in COPD patients and control subjects. At variance with previously reported data in peripheral airways [12] of COPD patients and in large airways from asthmatics [13], we did not find a significant increase in this MAPK in bronchial biopsy epithelium in mild/moderate and severe/very severe COPD or in peripheral tissue. This may be due, in part, to the presence and influence of a different inflammatory state of the airways when bronchial biopsies of asthmatics are compared to COPD patients. It is conceivable that a Th2 prevalent inflammatory state, such as in asthma, could better activate MAPK, including p-p38 MAPK. To better understand possible differences between asthma and COPD, we directly compared immune expression of activated MAPK in bronchial biopsies from COPD and asthmatic subjects, matched for age and sex, and we observed a significant increase in p-p38 MAPK in bronchiolar submucosa of mild asthmatics compared to stable COPD patients. Asthmatics also differed significantly from control non-smokers, confirming, in part, previously reported data [13]. In our asthmatics we found the most significant difference in the submucosal area rather than in epithelium, as previously reported [13]. This indicates that increased p-p38 MAPK levels in our asthmatics are mainly due to an increased infiltration of inflammatory cells. A Th2-type prevalent inflammation, such as in asthma, may also favour the highest p-p38 MAPK expression observed in the bronchi of asthmatics [29].

Inhalation of LPS in human volunteers induced activation of bronchial epithelium by increased expression of p38 MAPK and IL-8 [30]. P. aeruginosa-challenged human bronchial epithelial cells showed increased phosphorylation of p38 MAPK and IL-8 gene expression which was reduced by the use of p38 inhibitors [31]. Flagellin from P. aeruginosa increased the expression of IL-8 in BEAS-2B cells compared to untreated cells, and addition of p38 MAPK inhibitors reduced IL-8 expression [32]. IL-8 mRNA and protein expression was also increased after LPS stimulation of bronchial epithelial cells [33]. Poly(I:C) costimulation further increased IL-8 production which was reversed by dexamethasone and a p38 MAPK inhibitor [33].

Hydrogen peroxide increased Wnt-4 and IL-8 gene expression in BEAS-2B cells [34]. Wnt-4-stimulated 16HBE cells significantly increased IL-8 secretion and p38 MAPK activation [35]. A lower efficacy of corticosteroids is reported in human bronchial epithelial cells in asthma and COPD after oxidative stress challenge [2, 36]. In paediatric bronchial epithelial cells, Th2 cytokine challenge in the presence of rhinovirus-16 infection augmented IL-8 release [29]. Housedust mite-induced IL-8 release is blocked by an ERK inhibitor in human lung epithelial cells [37]. Our in vitro experiments show that 16HBE cells stimulated with H2O2, cytomix and LPS upregulated IL-8 mRNA expression, in agreement with previously report-
ed observations [30–37]. This was associated with upregulation of p38 MAPK but not JNK1 and ERK1 mRNA after H₂O₂ and LPS exposure. Interestingly, H₂O₂ also increased NF-kB p65 mRNA. These data suggest that in bronchial epithelial cells the p38 MAPK pathway may be more relevant after LPS and oxidative stimulation.

Our bronchial biopsy data, showing a significant increase in p-p38 MAPK immune positivity in mild asthmatics and its prevalence in stable COPD patients, taken together with our in vitro observations of increased p-p38 MAPKα mRNA after bronchial epithelial stimulation suggests that p-p38 MAPK activation may play a significant role in inducing bronchial inflammation in these diseases.

Recently, MacNee et al. [38] described an improvement in FEV₁ after 6 weeks of p38 MAPK inhibitor treatment in moderate-to-severe COPD patients. In contrast, a larger study, performed in moderate-to-severe stable COPD patients, treated with the highly selective oral p38 MAPK inhibitor isomapimod for 6 months, showed no significant changes in exercise tolerance or lung function [16]. This highlights the need to better define the clinical phenotype of patients in order to identify a likely ‘responder’ population of COPD patients [14, 15]. Our present results may contribute to this scope since p-p38 MAPK was certainly the most expressed MAPK in our bronchial specimens from asthmatics and COPD patients, and specific oxidative and inflammatory challenges, performed in 16HBE cells, showed a significant increase in p-p38 MAPKα mRNA after challenges. Since mononuclear cell infiltration was reported as the prominent cellular type in bronchiolar biopsies of mild/moderate but not of severe/very severe COPD patients [39], and p-p38 MAPK expression, reported in the submucosa of bronchiolar biopsies, is mainly due to immunostained mononuclear cells, we can argue, therefore, that selected populations including mild-to-moderate COPD patients with a more inflamed airway (cut-off values for mononuclear cell inflammation should be defined) and COPD patients during an exacerbation or those who frequently exacerbate, or asthmatic patients, could better respond to p38 MAPK inhibitors. The potential for combination therapies, particularly in exacerbated diseased patients, together with a deeper analysis of molecular events and possible activation of redundant inflammatory pathways, developing after p38 MAPK blockade, needs to be further studied.

Acknowledgements

This work was supported by the Fondazione Salvatore Maugeri, IRCCS, Ricerca Corrente.

I.M.A. is supported by the MRC-ABPI COPD-MAP consortium (G1001367/1) and the Welcome Trust (093080/Z/10/Z). Research at the National Heart and Lung Institute is also supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton NHS Foundation Trust and Imperial College London.

References


